Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06322238
Other study ID # 23-008706
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 2024
Est. completion date April 2026

Study information

Verified date May 2024
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug').


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 66
Est. completion date April 2026
Est. primary completion date April 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Subject must be = 18 years old 2. Subject must receive a 1st prescription (meaning no known prescription for this drug in the preceding 12 months) for a drug included in Table 1, which is prescribed to them in routine primary care. 3. Subject is able and willing to take part and willing to be followed up on for 48 weeks 4. Subject is able to donate saliva 5. Subject has signed informed consent 6. Subject meets requirement for computer access implying computer literacy as measured by active use of the patient portal or their email Exclusion Criteria: 1. For the investigational arm only: Previous (direct-to-consumer, or clinical) pharmacogenomic testing that includes any of the genes included in the Focused Pharmacogenomics Panel 2. Pregnant or lactating (to be verbally confirmed with the patient) 3. Life expectancy estimated to be less than three months as determined by patient receiving hospice care 4. Duration of index drug total treatment length is planned to be less than seven consecutive days. 5. Current inpatients 6. Unable to consent to the study 7. Unwilling to take part 8. Subject has no permanent address 9. Subject has no current primary care provider 10. Subject is, in the opinion of the study coordinator after discussion with participating clinician/pharmacist/investigator, not suitable to participate in the study 11. Patient has a diagnosis of stage 4 or 5 chronic kidney disease (CKD) or is receiving dialysis 12. Patients with advanced liver failure (stage Child-Pugh C) or a diagnosis of liver cirrhosis 13. History of a liver transplant or an allogeneic hematopoietic stem cell transplant 14. DNA sample collected that requires retesting in the event that DNA collected was not sufficient for testing as determined by the laboratory

Study Design


Related Conditions & MeSH terms

  • Drug Metabolism, Poor, CYP2C19-Related
  • Drug Metabolism, Poor, CYP2D6-Related
  • Drug-Related Side Effects and Adverse Reactions
  • Side Effect of Drug

Intervention

Diagnostic Test:
PGx panel test
In this prospective, non-randomized, step-wedge design controlled clinical study (PREPARE-MAYO Rochester, Mankato), pre-emptive genotyping of a panel of clinically relevant PGx-markers, for which CPIC guidelines are available.

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Adverse Drug Reaction (ADR) The count of participants who experience any of the following ADR's: muscle aches, falling, tripping, fainting, palpations, emotional changes, or physical changes 48 weeks
Secondary PREPARE-MAYO Clinicians' and pharmacists' Questionnaire. The 29-item PREPARE-MAYO Clinicians' and pharmacists' Questionnaire measures the Experience and Attitude, Knowledge, Knowledge testing and Needs assessment of clinicians and pharmacists. Each item is scored from 1 (disagree) to 4 (agree). Total possible scores range from 29 to 116, with lower scores indicating less knowledge and higher scores indicating more knowledge. 48 weeks
Secondary Patient-Reported Outcomes Measurement Information System (PROMIS-10) Global Health Questionnaire The 10-item PROMIS Global Health measures general, physical, mental and social health. Each item is scored from 1 (poor health) to 5 (excellent health). Total possible scores range from 10 to 50, with lower scores indicating worse state of health and higher scores indicating greater state of health. 48 weeks
See also
  Status Clinical Trial Phase
Completed NCT04696445 - Pharmacokinetics of Morphine and Oxycodone in Frail Elderly Undergoing Cardiac Surgery
Recruiting NCT01477242 - The Effect of Ondansetron During Intramuscular Ketamine Use in Children: A Trial in Emergency Department N/A
Recruiting NCT05775419 - Comparison of Chemoradiotherapy and Chemoradiotherapy Combined With Consolidation Chemotherapy for ESCC N/A
Completed NCT06035900 - Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate Phase 1
Completed NCT04475029 - Methadone in Cystectomy Patients N/A
Recruiting NCT03996941 - Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)
Recruiting NCT04701151 - NORTH-REG Dwell-Time Study Phase 4
Not yet recruiting NCT04644354 - The Efficacy of Nifedipine in the Management of Preterm Labor
Completed NCT03183908 - FLUAD® vs. Fluzone® High-Dose Study Phase 4

External Links